ResMed pioneers innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Its comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, the company improves quality of life, reduces the impact of chronic disease, and lowers costs for consumers and healthcare systems in more than 140 countries.
Company profile
Ticker
RMD
Exchange
Website
CEO
Michael Farrell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ResMed Corp. • ResMed (UK) Ltd • ResMed Asia Pacific Ltd • ResMed Beteiligungs GmbH • ResMed Holdings Pty Ltd • ResMed Pty Ltd • ResMed GmbH and Co • ResMed Motor Technologies Inc. • ResMed SAS • ResMed Paris SAS ...
IRS number
980152841
RMD stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
26 Jan 23
8-K
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023
26 Jan 23
8-K
Submission of Matters to a Vote of Security Holders
17 Nov 22
10-Q
2023 Q1
Quarterly report
27 Oct 22
8-K
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023
27 Oct 22
DEFA14A
Additional proxy soliciting materials
5 Oct 22
DEF 14A
Definitive proxy
5 Oct 22
10-K
2022 FY
Annual report
11 Aug 22
8-K/A
Regulation FD Disclosure
11 Aug 22
8-K
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2022
11 Aug 22
Transcripts
RMD
Earnings call transcript
2023 Q2
26 Jan 23
RMD
Earnings call transcript
2023 Q1
28 Oct 22
RMD
Earnings call transcript
2022 Q4
12 Aug 22
RMD
Earnings call transcript
2022 Q3
29 Apr 22
RMD
Earnings call transcript
2022 Q2
28 Jan 22
RMD
Earnings call transcript
2022 Q1
29 Oct 21
RMD
Earnings call transcript
2021 Q4
6 Aug 21
RMD
Earnings call transcript
2021 Q3
30 Apr 21
RMD
Earnings call transcript
2021 Q2
29 Jan 21
RMD
Earnings call transcript
2020 Q1
29 Oct 20
Latest ownership filings
4
Michael J. Farrell
17 Mar 23
4
Robert Andrew Douglas
16 Mar 23
144
Notice of proposed sale of securities
15 Mar 23
4
DAVID PENDARVIS
7 Mar 23
4
Kaushik Ghoshal
7 Mar 23
144
Notice of proposed sale of securities
3 Mar 23
4
Brett Sandercock
22 Feb 23
4
Robert Andrew Douglas
16 Feb 23
4
Michael J. Farrell
16 Feb 23
4
Brett Sandercock
14 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q4 2022
64.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 707 |
| Opened positions | 114 |
| Closed positions | 56 |
| Increased positions | 230 |
| Reduced positions | 232 |
| 13F shares | Current |
|---|---|
| Total value | 19.73 tn |
| Total shares | 95.06 mm |
| Total puts | 124.30 k |
| Total calls | 218.50 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 16.51 mm | $3.44 tn |
| BLK Blackrock | 13.19 mm | $2.75 tn |
| FMR | 6.81 mm | $1.42 tn |
| STT State Street | 6.36 mm | $1.32 tn |
| Capital World Investors | 5.05 mm | $1.05 tn |
| WCM Investment Management | 3.83 mm | $797.69 bn |
| Geode Capital Management | 3.13 mm | $653.62 bn |
| NTRS Northern Trust | 1.86 mm | $388.14 bn |
| IVZ Invesco | 1.86 mm | $387.99 bn |
| Ownership Capital B.V. | 1.41 mm | $293.92 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Mar 23 | Douglas Robert Andrew | ResMed Common Stock | Sell | Dispose S | Yes | Yes | 206.14 | 1,500 | 309.21 k | 258,026 |
| 15 Mar 23 | Douglas Robert Andrew | ResMed Common Stock | Gift | Dispose G | Yes | No | 0 | 1,919 | 0.00 | 259,526 |
| 15 Mar 23 | Farrell Michael J. | ResMed Common Stock | Sell | Dispose S | No | Yes | 206.9517 | 5,675 | 1.17 mm | 436,900 |
| 15 Mar 23 | Farrell Michael J. | ResMed Common Stock | Option exercise | Acquire M | No | Yes | 57.76 | 5,675 | 327.79 k | 442,575 |
| 15 Mar 23 | Farrell Michael J. | ResMed Common Stock Options ResMed Common Stock | Option exercise | Dispose M | No | Yes | 57.76 | 5,675 | 327.79 k | 48,865 |
| 3 Mar 23 | Kaushik Ghoshal | ResMed Common Stock | Sell | Dispose S | No | Yes | 220 | 1,000 | 220.00 k | 15,704 |
| 3 Mar 23 | David Pendarvis | ResMed Common Stock | Sell | Dispose S | No | Yes | 216.69 | 1,500 | 325.04 k | 94,172 |
| 17 Feb 23 | Sandercock Brett | ResMed Common Stock | Sell | Dispose S | No | Yes | 215.2196 | 10,000 | 2.15 mm | 106,880 |
News
$100 Invested In ResMed 5 Years Ago Would Be Worth This Much Today
17 Mar 23
$100 Invested In ResMed 10 Years Ago Would Be Worth This Much Today
8 Feb 23
JP Morgan Maintains Overweight on ResMed, Raises Price Target to $260
27 Jan 23
ResMed Q2 EPS $1.66 Beats $1.60 Estimate, Sales $1.03B Beat $994.02M Estimate
26 Jan 23
Hopeful Golden Cross Forms On ResMed's Chart
26 Jan 23
Press releases
ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum
15 Mar 23
ResMed's Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
13 Mar 23
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023
26 Jan 23
ResMed Appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to Become Chair Emeritus
26 Jan 23
ResMed Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference
2 Jan 23